The use of Baypamun N in crowding associated infectious respiratory disease: efficacy of Baypamun N (freeze dried product) in 4-10 month old horses.
The efficacy of an immunomodulator, Baypamun N, was tested in 4-10-month-old horses which were exposed to stress by weaning, transport and commingling with yearlings from different breeders (crowding). Verum (n = 26) and placebo animals (n = 27) received three intramuscular injections of the investigational preparations (days 0, 2, 9) starting at the day of commingling in one stable. The incidence of acute respiratory disease was high during the first 4 weeks after commingling. Approximately 50% of all horses showed seroconversion due to field infection by EHV1 and EHV4 during the observation period. The clinical scores in the Baypamun N group were significantly reduced by 40.3% (P < 0.05) compared to the placebo group. The proportion of horses with purulent nasal discharge during the observation period (4 weeks) was also significantly reduced by 58.7% (P < 0.01) in the Baypamun N group. Fifty per cent of the horses injected with Baypamun N showed no purulent nasal discharge and therefore no signs of complicated disease of the upper respiratory airways in contrast to only 14.8% in the non-protected placebo group. The challenge conditions studied in this investigation were rather severe because of the permanent exposure of Baypamun N treated individuals to the non-separated and untreated horses (n = 51). This indicates that treatment with Baypamun N is a successful tool to avoid severe clinical consequences of stress in young horses.
Ziebell
K L
KL
Bayer AG, Animal Health, Institute of Infectious Diseases, Leverkusen, Germany.
Steinmann
H
H
Kretzdorn
D
D
Schlapp
T
T
Failing
K
K
Schmeer
N
N
D000208:Acute Disease; D000276:Adjuvants, Immunologic / Q000008:administration & dosage / Q000592:standards / Q000627:therapeutic use*; D000818:Animals; D000914:Antibodies, Viral / Q000097:blood; D006566:Herpesviridae Infections / Q000517:prevention & control / Q000662:veterinary; D004861:Herpesvirus 1, Equid / Q000276:immunology; D006734:Horse Diseases / Q000209:etiology / Q000517:prevention & control*; D006736:Horses; D012141:Respiratory Tract Infections / Q000209:etiology / Q000517:prevention & control / Q000662:veterinary*; D013312:Stress, Physiological / Q000150:complications / Q000662:veterinary*; D018140:Varicellovirus / Q000276:immunology; D014765:Viral Vaccines / Q000008:administration & dosage / Q000592:standards / Q000627:therapeutic use*
D000276:Adjuvants, Immunologic; D000914:Antibodies, Viral; C076692:Baypamun HK; D014765:Viral Vaccines